GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15
CONCLUSIONS: We show for the first time that tumor produced GPX3 is necessary for ovarian cancer growth in vivo and that it regulates expression of GDF15. The immune profile associated with GPX3 expression in serous ovarian tumors suggests that GPX3 may be an alternate marker of ovarian tumors susceptible to immune check-point inhibitors.PMID:38342006 | DOI:10.1016/j.ygyno.2024.02.004 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 11, 2024 Category: Cancer & Oncology Authors: Caroline Chang Ya-Yun Cheng Shriya Kamlapurkar Sierra White Priscilla W Tang Amal T Elhaw Zaineb Javed Katherine M Aird Karthikeyan Mythreye R ébécca Phaëton Nadine Hempel Source Type: research
A comprehensive population-based study of malignant ovarian tumors, including histologic and immunohistochemical review, in children and adolescents 0-19 years old in Sweden between 1970 and 2014
CONCLUSIONS: Ovarian tumors in children and adolescents are rare and distinct from their adult counterparts regarding incidence and frequency. There was a strong concurrence between original and review diagnoses. The greatest diagnostic difficulty was subtyping of epithelial tumors and differentiating between tumors within the SCST group.PMID:38340646 | DOI:10.1016/j.ygyno.2024.01.035 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 10, 2024 Category: Cancer & Oncology Authors: Sandra Wessman Monica Nist ér Georgia Kokaraki Niklas Pal Giorgio Tettamanti Tirzah Braz Petta Joseph W Carlson Source Type: research
Survival rates in Hispanic/Latinx subpopulations with cervical cancer associated with disparities in guideline-concordant care
CONCLUSION: Significant differences in survival were identified among our cohort despite the receipt of guideline concordant care, with notably higher survival among Hispanic/Latinx populations.PMID:38340647 | DOI:10.1016/j.ygyno.2024.01.043 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 10, 2024 Category: Cancer & Oncology Authors: Andreea I Dinicu Shayan Dioun Yongzhe Wang Yongmei Huang Jason D Wright Ana I Tergas Source Type: research
Survival disparities in non-Hispanic Black and White cervical cancer patients vary by histology and are largely explained by modifiable factors
CONCLUSIONS: Histology matters in survival disparities and diagnosis at ≥65 years old between Black and White cervical cancer patients. These disparities were largely explained by modifiable factors.PMID:38340648 | DOI:10.1016/j.ygyno.2024.02.005 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 10, 2024 Category: Cancer & Oncology Authors: Calen W Kucera Nicole P Chappell Chunqiao Tian Michael T Richardson Christopher M Tarney Chad A Hamilton John K Chan Daniel S Kapp Charles A Leath Yovanni Casablanca Christine Rojas Collin A Sitler Lari Wenzel Ann Klopp Nathaniel L Jones Rodney P Rocconi Source Type: research
Prognostic value of three-tiered scoring system for lymph-vascular space invasion in endometrial cancer: A systematic review and meta-analysis
CONCLUSIONS: EC patients with focal and substantial LVSI had poorer survival, recurrence, and a higher incidence of lymph node metastasis than patients without LVSI. The substantial LVSI group was associated with even worse prognosis than the focal LVSI group. The three-tiered LVSI scoring system might effectively predict the prognosis of EC and guide clinical decision-making.PROTOCOL REGISTRATION: CRD 42023451793.PMID:38335803 | DOI:10.1016/j.ygyno.2024.01.046 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 9, 2024 Category: Cancer & Oncology Authors: Ling Han Yali Chen Ai Zheng Xin Tan Hengxi Chen Source Type: research
Identifying safe diagnostic algorithms for sentinel lymph node mapping in high-risk endometrial cancer: The SENTIREC-endo study
CONCLUSION: SLN-mapping is a safe staging procedure in women with high-risk EC if strictly adhering to a surgical algorithm including removal of any PET-positive lymph nodes independent of location and PLD or PLD and PALD in case of failed mapping.PMID:38335900 | DOI:10.1016/j.ygyno.2024.01.049 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 9, 2024 Category: Cancer & Oncology Authors: Sarah Marie Bj ørnholt Ole Mogensen Kirsten Bouchelouche Sara Elizabeth Sponholtz Erik Thorlund Parner Malene Grubbe Hildebrandt Annika Loft Gudrun Neumann Signe Frahm Bj ørn Katja Dahl Algirdas Markauskas Ligita Paskeviciute Fr øding Pernille Tine Jen Source Type: research
Authentic leadership in action: Experience gained from a gynecologic oncology fellowship leadership curriculum
Gynecol Oncol. 2024 Feb 7;182:176-178. doi: 10.1016/j.ygyno.2024.01.036. Online ahead of print.NO ABSTRACTPMID:38330810 | DOI:10.1016/j.ygyno.2024.01.036 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 8, 2024 Category: Cancer & Oncology Authors: Monica D Levine Vincent M Wagner Courtney J Riedinger Wafa Khadraoui Paulina J Haight Molly Morton David E Cohn Source Type: research
A systematic review of ethnic minority participation in randomised controlled trials of systemic therapies for gynecological cancers
CONCLUSIONS: Ethnic minorities formed smaller proportions of RCT cohorts compared to the general population. The majority of sites were located in North America and Europe, with few in other regions, limiting enrollment of South Asian, South-East Asian and African patients in particular. Efforts to recruit more ethnic minority patients should be made in North America and Europe. More sites in underserved regions would promote equitable access to RCTs and ensure findings are generalisable to diverse groups. This review assessed the global population enrolled in contemporary RCTs for novel therapies now routinely given for g...
Source: Gynecologic Oncology - February 8, 2024 Category: Cancer & Oncology Authors: Luke Steventon Shibani Nicum Kenneth Man Ubonphan Chaichana Li Wei Pinkie Chambers Source Type: research
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis
CONCLUSION: There has been a decrease in the incidence and incidence-based mortality of ovarian, fallopian tube, and primary peritoneal cancer, primarily due to reductions in advanced stage epithelial cancers originating in the ovary, fallopian tube, or peritoneum.PMID:38330833 | DOI:10.1016/j.ygyno.2024.01.034 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 8, 2024 Category: Cancer & Oncology Authors: Sahana Somasegar Ravali A Reddy Stephanie Chow Oliver Dorigo Malte Renz Amer Karam Source Type: research
Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial
CONCLUSIONS: Despite some early, largely transient increases in gastrointestinal symptoms, patients with OC treated with niraparib first-line maintenance therapy reported no worsening in overall HRQoL.PMID:38325276 | DOI:10.1016/j.ygyno.2024.01.021 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 7, 2024 Category: Cancer & Oncology Authors: Bhavana Pothuri Sileny Han Dana M Chase Florian Heitz Robert A Burger Lydia Gaba Linda Van Le Eva Guerra David Bender Jacob Korach Noelle Cloven Cristina Churruca Philippe Follana Paul DiSilvestro Jean-Fran çois Baurain Kris Jardon Carmela Pisano Ulla Pe Source Type: research
Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?
CONCLUSIONS: In this national cohort study, <30% of patients ever used telemedicine, and significant racial and regional disparities existed in utilization. Telemedicine expansion efforts should include programs to improve equity in access to telemedicine.PMID:38320467 | DOI:10.1016/j.ygyno.2024.01.047 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 6, 2024 Category: Cancer & Oncology Authors: Anna Jo Bodurtha Smith Emily G Gleason Leslie Andriani Jonathan Heintz Emily M Ko Source Type: research
Social determinants of health in uterine carcinosarcoma
CONCLUSIONS: Racial disparities were seen in median household income. Most SDOH independently analyzed in this study did not affect OS. The complex interaction between race and stage in UCS survival outcomes needs further investigation.PMID:38309028 | DOI:10.1016/j.ygyno.2024.01.042 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 3, 2024 Category: Cancer & Oncology Authors: Larissa L Aroche Gutierrez Donald D McIntire Jayanthi Lea Salvatore LoCoco David Scott Miller Source Type: research
Short-term survival analysis of a risk-adjusted model for ovarian cancer care
CONCLUSION: Ovarian cancer care at a High-O/E hospital is an independent predictor of improved outcome and the survival advantage is disproportionately weighted toward the short-term time horizon following diagnosis.PMID:38309029 | DOI:10.1016/j.ygyno.2024.01.005 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 3, 2024 Category: Cancer & Oncology Authors: Anjali Hari Jenny Chang Carolina Villanueva Argyrios Ziogas Veronica Vieira Robert E Bristow Source Type: research
Evaluation of prognostic potential of β-catenin and L1CAM expression according to endometrial cancer risk group
CONCLUSION: The expression of nuclear β-catenin may serve as a potential biomarker for predicting recurrence and guiding therapeutic strategies in high-intermediate risk EC patients.PMID:38309030 | DOI:10.1016/j.ygyno.2024.01.044 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 3, 2024 Category: Cancer & Oncology Authors: Heesoo Yoon Dong Hoon Suh Kidong Kim Jae Hong No Yong Beom Kim Hyojin Kim Source Type: research
Rural-urban disparities in psychosocial functioning in epithelial ovarian cancer patients
CONCLUSION: Rural patients reported less improvement in psychological functioning in the year following diagnosis than their urban counterparts. Clinicians should be aware of rurality as a potential risk factor for ongoing distress. Future studies should examine causes of these health disparities and potential long-term inequities and develop interventions to address these issues.PMID:38309031 | DOI:10.1016/j.ygyno.2024.01.024 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - February 3, 2024 Category: Cancer & Oncology Authors: Rachel Telles M Bridget Zimmerman Premal H Thaker George M Slavich Edgardo S Ramirez Sharaf Zia Michael J Goodheart Steven W Cole Anil K Sood Susan K Lutgendorf Source Type: research
